Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)
Jim Zhong(University of Leeds), Ann Henry(University of Leeds), Andrew Scarsbrook(University of Leeds), C. Eccles(University of Manchester), Peter Hoskin(University of Manchester), Robert Chuter(University of Manchester), Maria Aparecida Alves de Oliveira Serra(Institute of Cancer Research), Ananya Choudhury(University of Manchester), Christopher C. Thompson(Brigham and Women's Hospital), Michael J. Dubec(University of Manchester), Y. Tsang(Mount Vernon Cancer Centre), Sarah Brown(University of Leeds), N. Jane Taylor(Mount Vernon Hospital), Catharine West(University of Manchester), Rachel Reed(Dana-Farber Cancer Institute), David L. Buckley(University of Florida), Pam Shuttleworth(St James's University Hospital), Peter Bownes(Mount Vernon Hospital), Kimberley J. Reeves(University of Manchester), Damien J. McHugh(University of Manchester)
Cited by 15
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
|Nature Genetics|2018|1k
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
|Clinical and Translational Radiation Oncology|2018|932